AI-Powered News Analysis•Compare coverage across the political spectrum

#pharmaceutical

Related Stories (18)

Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters

Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters

October 9, 2026

AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters

AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters

October 2, 2026

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com

September 29, 2026

Merck's drug for diabetes-related eye disease meets trial goal - Reuters

Merck's drug for diabetes-related eye disease meets trial goal Reuters

September 24, 2026

US FDA extends review of Exelixis' cancer drug - reuters.com

US FDA extends review of Exelixis' cancer drug reuters.com

September 11, 2026

Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial - Reuters

Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial Reuters

September 3, 2026

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters

August 17, 2026

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says - Reuters

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says Reuters

August 5, 2026

Eli Lilly to offer early access to next-gen obesity drug to some patients - Reuters

Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters

August 3, 2026

Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial - Reuters

Novo Nordisk's anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial Reuters

July 31, 2026

Merck's cholesterol pill gets US FDA approval - Reuters

Merck's cholesterol pill gets US FDA approval Reuters

July 16, 2026

Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Reuters

Celcuity shares fall as launch delay eclipses US approval for breast cancer drug Reuters

July 15, 2026

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug - Reuters

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug Reuters

June 22, 2026

US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters

US FDA approves Axsome's drug for Alzheimer's-related agitation Reuters

April 30, 2026

US FDA approves J&J's oral psoriasis pill - Reuters

US FDA approves J&J's oral psoriasis pill Reuters

March 18, 2026

Novo Nordisk to halve US list price of Wegovy from 2027 - Reuters

Novo Nordisk to halve US list price of Wegovy from 2027 Reuters

February 24, 2026

Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters

Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters

February 23, 2026

Trump meets Novartis CEO, says drugmaker building 11 US plants - Reuters

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWkRNOGVDMjdOeVNCcTZaWXAyQ1Jld0RoTnZYR19TUTMwQXpqTUdtZHVxUWR6blNTbG9hTFdnV0pjRGtWVWl6aU9CWjM4THZYN0tMZHBMd0w4ajFDT0NjbkwybjJXeFFObUZSMmZ0TTdLWVlId0oxLUE2OFNkUUFvaUJwel96U0VQZjJJbW5EcUhpZHpDRmI5N09FOEw3a0FsbmsxcGNla3NSdw?oc=5" target="_blank">Trump meets Novartis CEO, says drugmaker building 11 US plants</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

February 20, 2026

Related Pages (13)

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•October 9, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•September 30, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•September 24, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•September 11, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•August 5, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•July 31, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•July 16, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•July 15, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•May 1, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•March 18, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•February 24, 2026

Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial

Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing

english.aaj.tv•February 24, 2026

Untitled

window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa

news.google.com•February 20, 2026